Ascentage Pharma Group International (NASDAQ:AAPG) Reaches New 12-Month Low – Here’s What Happened

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) reached a new 52-week low on Thursday . The stock traded as low as $15.40 and last traded at $15.1410, with a volume of 3803 shares. The stock had previously closed at $16.00.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. BTIG Research restated a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a report on Friday, August 21st. Raymond James Financial reiterated a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. Finally, B. Riley Financial assumed coverage on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. They set a “buy” rating and a $45.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $46.43.

Ascentage Pharma Group International Stock Performance

The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.18 and a current ratio of 1.22. The stock’s 50 day simple moving average is $17.77 and its two-hundred day simple moving average is $20.16.

Ascentage Pharma Group International (NASDAQ:AAPG) last issued its earnings results on Wednesday, August 19th. The company reported ($0.65) EPS for the quarter. The firm had revenue of $22.24 million for the quarter. On average, sell-side analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -2.42 EPS for the current fiscal year.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a biopharmaceutical company focused on discovering and developing therapies that target apoptosis, the natural process of programmed cell death. Its research is directed primarily toward cancer and other serious diseases in which abnormal cell survival contributes to disease progression.

The company’s pipeline includes small-molecule drug candidates designed to inhibit proteins involved in apoptosis regulation, including BCL-2, MDM2 and inhibitor-of-apoptosis proteins.